Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Prostatic Neoplasms 241Lymphoma 178Lymphoma, Large B-Cell, Diffuse 172Precursor Cell Lymphoblastic Leukemia-Lymphoma 87Lymphoma, Follicular 79Lymphoma, Non-Hodgkin 73Burkitt Lymphoma 66Multiple Myeloma 64Leukemia 57Hodgkin Disease 45Lymphoma, Mantle-Cell 41Neoplasms 35Lymphoma, T-Cell, Peripheral 31Lymphoma, B-Cell 30Lymphoma, B-Cell, Marginal Zone 28Lymphoma, Large-Cell, Anaplastic 26Neoplasm Metastasis 25Lymphoma, Large-Cell, Immunoblastic 24Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Neoplasms, Plasma Cell 21Recurrence 20Immunoblastic Lymphadenopathy 15Dendritic Cell Sarcoma, Interdigitating 15Lymphoma, T-Cell 14Leukemia, Biphenotypic, Acute 10Waldenstrom Macroglobulinemia 9Blast Crisis 9Primary Myelofibrosis 8Myelodysplastic Syndromes 8

Interventions

Amifostine 19Cisplatin 15Radiotherapy 13Etoposide 10Cyclophosphamide 9Carboplatin 8Paclitaxel 7Filgrastim 7Drug Therapy 5Cytarabine 5apatinib 4Methotrexate 4sodium thiosulfate 3Methylprednisolone 3Gemcitabine 3Docetaxel 3sargramostim 2pegfilgrastim 2glucarpidase 2etoposide phosphate 2denileukin diftitox 2camrelizumab 2Voriconazole 2Vincristine 2Social Determinants of Health 2Pyridoxine 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Mitoxantrone 2Melphalan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Prednisone × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡